M
Mihaela C. Munteanu
Researcher at Cephalon
Publications - 18
Citations - 649
Mihaela C. Munteanu is an academic researcher from Cephalon. The author has contributed to research in topics: Bendamustine & Mantle cell lymphoma. The author has an hindex of 8, co-authored 16 publications receiving 556 citations.
Papers
More filters
Journal ArticleDOI
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Ian W. Flinn,Richard van der Jagt,Brad S. Kahl,Peter Wood,Tim E. Hawkins,David MacDonald,Mark Hertzberg,Yiu Lam Kwan,David Simpson,Michael Craig,Kathryn S. Kolibaba,Samar Issa,Regina Clementi,Doreen M. Hallman,Mihaela C. Munteanu,Ling Chen,John M. Burke +16 more
TL;DR: Data indicate BR is noninferior to standard therapy with regard to clinical response with an acceptable safety profile, and this trial was registered at www.clinicaltrials.gov as #NCT00877006.
Journal ArticleDOI
An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study
Ian W. Flinn,Richard van der Jagt,Brad S. Kahl,Peter Wood,Tim E. Hawkins,David MacDonald,Mark Hertzberg,Yiu-Lam Kwan,David Simpson,Michael Craig,Kathryn S. Kolibaba,Samar Issa,Mihaela C. Munteanu,Regina Clementi,Ling Chen,John M. Burke +15 more
TL;DR: In this paper, the authors compared efficacy and safety of BR with standard treatment regimens of R-CHOP and R-CVP as first-line treatment for indolent NHL or MCL.
Journal ArticleDOI
Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.
Myron S. Czuczman,Stephen Kahanic,Andres Forero,Glen L. Davis,Mihaela C. Munteanu,Eric Van Den Neste,Fritz Offner,Dominique Bron,Donald Quick,Nathan Fowler +9 more
TL;DR: In patients with treatment-naive, indolent B cell NHL, bendamustine-ofatumumab exhibited a high degree of activity (90 % ORR), comparable with historical bendamUSTine-rituximab ORRs (≥90 %), and was adequately tolerated (ClinicalTrials.gov identifier: NCT01108341).
Journal ArticleDOI
Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Myron S. Czuczman,Andre Goy,Dominick Lamonica,D. A. Graf,D. A. Graf,Mihaela C. Munteanu,R. van der Jagt +6 more
TL;DR: Bendamustine-rituximab is an effective therapy with manageable toxicity in relapsed/refractory MCL and ORR and CR rate compared favorably with single-agent ibrutinib.
Journal ArticleDOI
18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.
TL;DR: Compared with positive end-of-treatment 18F-FDG PET, negative scans, indicating a CMR, were predictive of improved 1-y survival, duration of response, and overall survival for patients with relapsed or refractory MCL receiving BR.